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1. Introduction 
Calcineurin inhibitors (CNIs) are maintenance immunosuppressive drugs that have been 
used as the main therapy for organ transplantation for many years. Of the CNIs, 
cyclosporine (CYA) and tacrolimus (TAC) are used in clinical practice. The CYA binding 
protein is cyclophilin and that of TAC is FK-binding protein (FKBP), but both drugs have 
same mechanism of action: the inhibition of interleukin 2 (IL-2) production by binding the 
binding protein complex to calcineurin (CN). It is thought that the area under the 
concentration time curve (AUC) for both drugs may be the pharmacokinetic (PK) parameter 
that is the most associated with clinical effect. However, oral CYA administration gave a 
blood concentration–time curve with a high CYA peak concentration (Cp), and oral TAC 
showed a gradual blood concentration–time curve, keeping at the minimum of the 
therapeutic range; both drugs vary significantly in their pharmacokinetics1). The Cp of CYA 
has increased since the Neoral® preparation of CYA was used, compared with 
Sandimmune®, whereas the Cp of TAC decreased since using a sustained release 
preparation; thus the differences between CYA and TAC are considerable2). Although the 
optimal pharmacokinetics of both drugs may be similar to those of other drugs with the 
same mechanism of action, no conclusions have been reached on whether the peak blood 
concentration, or a specific maintained blood concentration, is required for CNI 
pharmacokinetics, even if both drugs show identical AUCs. In addition, although CYA and 
TAC are similar CNI drugs, there are differences in the recommended monitoring points of 
CYA and TAC; these points are the C2 level (the blood concentration 2 h after oral 
administration), which mainly reflects Cp, and the trough concentration (Ct)3-8), respectively9-
11). To solve these problems, it is necessary to consider comprehensively not only AUC, but 
also Cp, Ct, and time above the minimum effective concentration (%T > MEC). We discuss 
the optimal pharmacokinetics of CNIs by comparing various aspects of CYA and TAC. 
2. Which parameter is the most closely associated with clinical results? 
2.1 Cyclosporine 
It is a well-known fact that Ct is associated with clinical effect. As when the Ct become 
higher, the AUC and the Ct p are consequently higher. it is not surprising that Ct, Cp, and 
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AUC are all correlated with clinical effect. The question, therefore, is which of these PK 
parameters is the most associated with clinical effect. It is commonly thought that the AUC 
of CYA is most closely associated with clinical effect12,13). However, it is often difficult to 
measure AUC0–12 for 12 h after administration in clinical practice. Accordingly AUC0–4 (the 
area under the concentration time curve at 0–4 h following oral administration) is generally 
used as an alternative absorption phase to AUC0–12. This earlier blood sampling point that 
has been used since the introduction of cyclosporine microemulsion preconcentrate 
(Neoral), in which oral absorption is significantly stabilized3,14,). Even AUC0–4 requires 
several blood sampling points, and this causes problems such as increased burden on 
patients, cost, and medical staff duties. It has therefore been recommended that a single 
blood sampling point, C2, be used; this is the sampling point at which the majority of 
patients show peak level in the absorption phase, and is better correlated with AUC0–12 than 
C03-8). It has been reported that AUC0–4 and C2 are associated with the incidence rate of acute 
rejection and nephropathy or similar conditions3,15-19), and a relationship with clinical effects 
and side effects was demonstrated. Nevertheless, there are several problems relating to the 
use of C2 because its determination involves the measurement of absorption values. As it 
means the change in blood concentration over time is great; there is a possibility that C2 may 
vary significantly over a small interval in blood sampling times, in comparison with trough 
value 20,21), and complicated procedures for outpatients are increased. Given the above, the 
monitoring of C2 in routine clinical practice is questionable 22,23), and it has been reported 
that there is little evidence in which it is useful to monitor C224
）.  
2.2 Tacrolimus 
On the other hand, the AUC of TAC, like that of CYA, is commonly considered to be a 
parameter which is highly associated with clinical effect, despite little evidence for TAC 
treatment showing clinical effects such as acute rejection25,26）or side effects such as 
nephrotoxicity27). Therefore, TAC was examined to show which blood sampling point is the 
best correlated with AUC as CYA. One study reported that Co is the best correlated with 
AUC27), whereas another study suggested that a formula with fewer blood sampling points, 
and not Co, is the most closely correlated with AUC (limited sampling strategy) 28-31). 
Thus, although the AUC of CNIs is regarded as the PK parameter, which is the most closely 
associated with clinical effect, its monitoring point is not clear. In addition, it has not been 
much discussed whether the peak blood concentration, or a specific maintained blood 
concentration, is required for pharmacokinetics even if both drugs show identical AUC. For 
the purpose of solving this problem, the authors analyzed the pharmacokinetics of CYA and 
TAC by comparing AUC, Cp, and Ct parameters, used not as independent parameters but in 
a new manner, which could indicate the interrelationship between these parameters. 
2.3 Comparison between pharmacokinetics of oral cyclosporine and tacrolimus
1)
  
There has been no study comparing the differences between the blood concentration time 
curves of CYA and TAC in detail. Therefore, the authors thought that the pharmacokinetics 
of both drugs could be compared by using the blood concentration (C/D/BW), adjusted for 
dose per body weight. Although the AUC/(D/BW) of both CYA and TAC, which should 
show the relative availabilities, was equal, the Cp/(D/BW) of CYA was comparatively 
higher than that of TAC and, on the other hand, the Ct/(D/BW) of CYA was lower than that 
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of TAC, which illustrated a blood concentration time curve with a sharp peak. On the other 
hand, the pharmacokinetics of TAC showed that the Cp/(D/BW) of TAC was lower and the 
Ct/(D/BW) was higher, which illustrated a gently hunched blood concentration time curve, 
which was similar to the curve for continuous intravenous infusion (Figure 1, Table 1). 
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Fig. 1. Comparison of the mean blood concentration-time curves for CYA (n=20) and TAC 
(n=24) 
CYA TAC
p value
(n = 20) (n = 24)
AUC/䠠/䠞Ｗ(ng/mL・h)/(mg/kg) 2323±447 2507±1255 N.S.
Cｐ/Cｔ 6.00±1.78 1.93±0.43 <0.0001
䠟ｐ/䠠/䠞Ｗ(ng/mL)/(mg/kg) 433.1±90.3 292.6±135.7 <0.005
Cｔ /䠠/䠞Ｗ(ng/mL)/(mg/kg) 77.1±23.6 160.0±91.8 <0.005
AUTL/AUC䠄%) 41.9±6.9 73.4±8.1 <0.0001
䠄Takeuchi H. Biol Pharm Bull. 2008 䠅  
Table 1. Comparison of pharmacokinetic parameters between CYA and TAC 
Thus, even if the AUC of both drugs were equal, the pharmacokinetics of the both drugs is 
totally different, from the viewpoint of the correlation with each peak value and each trough 
value. We developed AUTL/AUC% (percentage of the area under the trough level in the 
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area under the blood concentration) in order to assess the interrelationship between AUC, 
Cp, and Ct in comparing CYA and TAC (Figure 2). As a result, the AUTL/AUC% of CYA 
was as low as 41.9%, and the AUC had a higher percentage of dependence on Cp than on Ct. 
On the contrary, the AUTL/AUC% of TAC was as high as 73.4%, and the AUC had a higher 
percentage of dependence on Ct than on Cp (Figure 3).  
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Fig. 2. Blood concentration curve and pharmacokinetic parameters 
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Fig. 3. Comparison of the pharmacokinetic parameters of AUTL/AUC% between CYA and 
TAC. 
To demonstrate these results further, we examined the correlation between the AUC and the 
area above trough level (AATL) or AUTL, and found that these results were consistent with 
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the theory that CYA had higher correlation with AATL, and TAC had higher correlation 
with AUTL (Table 2). If AUC is most closely associated with clinical effect, it may be 
appropriate to monitor Cp and Ct for CYA and TAC, respectively. However, considering 
that the blood concentration per unit time for Cp changes dramatically, and taking into 
account the measurement convenience and complexity of the methods, it is thought that 
TAC to measure Ct is preferable as a drug to perform TDM than CYA to recommend 
measuring C2. However, it is thought that Ct as monitoring paint is not a clinical problem, 
as the measurement of CYA Ct reflects the AUC adequately.  
 
Table 2. Comparison of correlation coefficients between AUC and AUTL or AATL in CYA- 
and TAC-treated recipients 
Furthermore, the influences on clinical effect, such as effectiveness or side effects, would be 
different between pharmacokinetics with a higher peak value, namely with low 
AUTL/AUC% and pharmacokinetics with a maintained minimum effective concentration, 
namely with high AUTL/AUC%, such as the blood concentration of continuous intravenous 
infusion, even if the AUC of both drugs were equal. By illustrating this, as shown in Figure 
4, it is possible to see a difference between the pharmacokinetics of A and B, even if both 
AUCs are equal. The Cmax of A is lower than that of B but the Cmin of A is higher than that of 
B. This relation can be applied to the correlation of CYA and TAC discussed above.  
In addition, considering PK parameters involved pharmacodynamics (PD) such as the 
minimum effective concentration (MEC), A may maintain MEC over a certain time  
(%T > MEC), which is longer than for B, even if the AUCs for both A and B are equal. CNIs 
may be a drug for which time above MIC (MEC) is associated with drug efficacy, as is the 
case with antimicrobial agents such as beta-lactam antibiotics, This suggests that the effects 
of A and B may be different, by the correlation of AUC, Cp, and Ct. 
Thus, the examination of clinical effect using only AUC is limited, and therefore, an analysis 
including the interrelationship between AUC, Cp, Ct, and time is required. 
3. Correlations among AUTL/AUC%, effects, side effects, and PK parameters 
for other drugs practicing TDM 
Table 3 shows the results of correlations among the PK parameters, effects, and side effects 
of current drugs investigated for TDM in the literature. As a result, the blood concentration 
time curves can be classified into the following categories: a drug group showing a sharp 
peak curve (AUTL/AUC < 50%, Cp/Ct > 6), such as aminoglycoside antibiotics (AGs), and a 
drug group showing a gentle peak curve (AUTL/AUC% > 60％, Cmax/Cmin < 2), such as 
antiarrhythmic drugs, bronchodilators, and anticonvulsant drugs (Figure 5). 
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AUC䠖A=B
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Fig. 4. Pattern diagrams in the case that Cp, Ct, and MEC time are different, even though 
AUC is the same. 
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Table 3. AUTL/AUC%, Cp/Ct, and parameters of the efficacy and side effect of drugs that 
are used in therapeutic drug monitoring (TDM) 
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Fig. 5. Two patterns of blood concentration curve based on AUTL/AUC% 
All drugs except AGs, glycopeptide antibiotics, and CYA, which required AUTL/AUC% 
≥60% and Cp/Ct ≤2 to maintain the therapeutic range, had a gentle blood concentration 
time curve and the monitoring point was Ct. It is preferred that AGs maintain a 
concentration to the peak value for as long as possible, but it must be reduced to below a 
specific blood concentration on a temporary basis to avoid nephrotoxic side effects. 
Therefore, AUTL/AUC% decreased to a low level and Cp/Ct increased to a high level to 
show a blood concentration time curve with a sharp peak. Furthermore, AGs have a post-
antibiotic effect (PAE), so that it can maintain its effect even if it falls below the 
therapeutic range. 
Furthermore, the pharmacokinetics of AGs and glycopeptide antibiotics relate to 
administration by injection, and these drugs are not required to control a clinical condition 
for a long period. Therefore, the results showed that CYA (Neoral) was the only oral drug 
used for prevention of a long-term pathologic condition that showed a sharp peak curve. 
Drugs with a sharp peak concentration were the only drugs for which the blood 
concentration needed to be reduced on a temporary basis to avoid side effects, and there 
was no drug that needed to be at peak concentration in order to have an effect. However, 
when the CYA used was switched from Sandimmune to Neoral to increase and stabilize 
absorption, the absorption rate constant (Ka) became large such that the peak value 
necessarily increased, and the AUTL/AUC% decreased.  
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CYA may not require higher peak concentration, if the trough concentration can be higher to 
keep the AUC, although it is impossible that raising the trough value and decreasing the 
peak value (to increase the AUTL/AUC%) using the existing CYA formulation, keep the 
AUC. 
4. Optimal pharmacokinetics based on PK/PD analysis 
In connection with the preceding paragraph, regarding patients treated with CYA (Neoral), 
it has been reported that the inhibitory action of CN was in proportion to the blood 
concentration following administration32), and that IL-2 was stably suppressed at the peak 
value rather than the trough value33). On the other hand, another report showed that TAC 
above a certain level continuously had an inhibitory action of CN after administration34). It 
is possible that the differences between the both drugs may contribute to these results 
(Figure 6). In other words, CYA shows sufficient CN inhibitory action at the peak value, but 
the data suggests that the CN inhibitory action may be insufficient at the trough value. On 
the other hand, TAC is at a concentration that shows a certain level of CN inhibitory action 
throughout all time points, including the trough value, which suggests that it may always 
show inhibitory action of CN above a certain concentration.  
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Fig. 6. Relationship between blood concentration and calcineurin activity in CYA and TAC. 
The authors analyzed the relationship of the concentration—lymphocyte proliferation rate 
curves (PD) of CYA and TAC with the target blood concentration (PK) and found that 
lymphocyte proliferation was completely suppressed at the trough level of TAC. On the 
other hand, CYA had a low inhibition ratio at the trough value and was more than sufficient 
inhibited at the peak value, so that there was no need for the concentration to be as high as 
the peak value in terms of pharmacodynamics; consequently, it was necessary to make the 
trough value higher (Figure 7). 
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Fig. 7. Relationship between average concentration-lumphocyte proliferation rate curves 
and target blood concentration of calcineurin inhibitors. 
5. Optimal blood concentration for continuous intravenous infusion based on 
AUC 
Currently, intermittent intravenous administration and 24-h continuous intravenous 
administration can be compared for optimal pharmacokinetics in clinical practice. 
For patients undergoing hematopoietic stem cell transplantation, drugs are administered by 
intravenous injection for relatively long periods, from several weeks to several months, 
because ingestion is not possible. However, the theoretical optimum targeted blood 
concentration for continuous infusion has never been clearly determined. If AUC is the 
parameter most closely associated with clinical effect, it can be considered correct, in theory, 
to adjust the blood concentration of oral and intravenous administration to the level that 
achieves the same AUC. We used the AUTL (area under trough level) parameter developed 
by the authors to calculate the target blood concentration for continuous intravenous 
infusion from the trough level for oral administration35,36). As a result, the target blood 
concentration for continuous intravenous infusion of TAC (Css) was 1.4 times that of the Ct 
because AUTL/AUC% is large. These results were almost close to the blood concentration 
in the present practice of continuous intravenous infusion. Meanwhile, CYA has a small 
AUTL/AUC% so that a trough value 2.55 times higher and a considerably high Css were 
required in theory (Figure 8). 
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Fig. 8. Formula for calculating Css from Ct, and the relationship between the AUC of oral 
administration and continuous intravenous infusion. 
In actual hematopoietic stem cell transplantation, it has been reported that continuous 
intravenous infusion of CYA at 250–400 ng/mL Css, which is lower than the theoretical 
value, showed lower nephrotoxicity than intermittent intravenous administration twice a 
day, and that the incidence rate of acute graft-versus-host disease (GVHD) was high37). 
However, in a study by the same group, comparing a 300 ng/mL Css group with a  
500 ng/mL Css group, it was reported that the incidence rates of acute and chronic GVHD 
were significantly lower in the 500 ng/mL group, and there was no difference in side effects, 
such as nephrotoxicity, between both groups of the trial38). In another study by Miller et al. 
using a Css of 450–500 ng/mL, similar results on acute GVHD and tolerability were 
reported39) and these reports were consistent with the authors’ hypothesis. Continuous 
intravenous infusion is the ultimate method for maintaining a minimum effective 
concentration (Figure 4-A), and it may be possible for the pharmacokinetics to have no peak 
if the AUC of CYA can be obtained; in other words, the pharmacokinetics as minimum 
effective concentration is maintained.  
Meanwhile, in many institutions, patients undergoing hematopoietic stem cell 
transplantation received different dosages, such as 3 mg/kg/day twice a day  
(3 h continuous infusion) by I.V. infusion, once a day (4 h continuous infusion) by  
I.V. infusion, once a day (10 h continuous infusion) by I.V. infusion, and 24 h continuous 
intravenous. However, there are slight differences in the clinical results40). Each AUC was 
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almost the same, at around 11,000 ng·h/mL, in all the dosages above, but the results 
calculated by the authors revealed that each AUTL/AUC% was approximately equal  
(35–44%) in intermittent administration and it was 100% in continuous intravenous 
infusion (Figure 9). Moreover, we set various therapeutic ranges to simulate and calculate  
%T > MEC and found that the values significantly varied depending on MEC (Figure 10). 
These results suggest that CYA has a wide tolerance of blood concentration in terms of 
action and side effects, and that all dosages might be clinically equal.  
 
 
Fig. 9. Comparison of pharmacokinetic parameters among various administration methods 
of CYA in hematopoietic stem cell transplants. 
For TAC, it has already been shown in a clinical trial that numerous side effects, such as 
nephropathy or neurologic symptoms, are caused by twice daily intermittent intravenous 
administration. Therefore, the package insert indicates that it should be administered by 24 
h continuous intravenous administration, and it is known that continuous intravenous 
administration is appropriate. It may be because the method for oral use has a large 
AUTL/AUC% and no high peak, whereas intravenous injection twice a day by high speed 
drip has a high peak. It is considered that the effect range and the side effect range of TAC 
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may be closer than those of CYA and that pharmacokinetics showing a gentle blood 
concentration time curve (large AUTL/AUC%) may be suitable. 
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Fig. 10. T%>MEC of various CYA administration methods for each MEC in hematopoietic 
stem cell transplants. 
6. Pharmacokinetic differences between morning and evening 
In studies monitoring the blood concentration of CYA and TAC for 24 h and comparing 
the pharmacokinetics of morning and evening, some studies reported that there was no 
difference in pharmacokinetics between morning and evening41,42), whereas several other 
studies reported that there was a difference43-45). In the authors’ data, the AUC0–12, AUC0–4, 
C2, and Cmax following evening administration were significant lower than those 
following morning administration both in patients treated with CYA and patients treated 
with TAC46,47) (Figure 11). As TAC shows gradual blood concentration–time curve in 
comparison with CYA, TAC is hardly affected by delayed or reduced absorption in the 
evening, so that the differences between various PK parameters between morning and 
evening were smaller in TAC (Table 4). Therefore, a drug such as TAC, which shows 
pharmacokinetics with a large AUTL/AUC% may have potential benefits because it has 
little difference in pharmacokinetics between morning and evening. However, a sustained 
release preparation of TAC administered once a day has been launched and its 
pharmacokinetics has no peak value in the evening because it is administered only in the 
morning, but its efficacy is equal to that of a drug administered twice a day. From this 
fact, it is possible that the pharmacokinetic difference between morning and evening is 
not a clinical problem. 
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Fig. 11. Comparison of blood concentration-time curves through 24 hours between CYA and 
TAC. 
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Table 4. Comparison of pharmacokinetic parameter ratios of evening to morning 
administrations between TAC and CYA 
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7. Calculation of optimal dose and blood trough concentration on switching 
between CYA and TAC 
The authors calculated the optimal dose and the Ct concentration on switching between 
CYA and TAC, with a comparison of the pharmacokinetics (AUC, Cp, and Ct) of CYA and 
TAC. AUC/D/BW is equal, but the Ct of TAC is relatively higher than that of CYA as a 
result of the pharmacokinetic differences; considering this, the dosage ratio is as follows: 
CYA:TAC = 25:1, and the targeted Ct ratio is as follow: CYA:TAC = 13:148,49) (Figure 12). 
These reduced values were equal to the titer ratio calculated from the IC50 value of the PD 
data. 
 
 
 
Fig. 12. Conversion rate of dose and target trough level derived from pharmacodynamic and 
pharmacokinetic analyses.  
8. Conclusion 
Although both CYA and TAC belong to CNIs and the availabilities (AUC/D/BW) are the 
same, significant differences in the pharmacokinetics (blood concentration-time curve) of 
both drugs were found. Given that the AUC is the parameter that is most closely 
associated with clinical effect, it is optimal to monitor Cp and Ct for oral CYA and TAC, 
respectively.  
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However, even if both drugs show identical AUC, the clinical effects, such as effectiveness 
or side effects, may vary according to differences in the blood concentration time curve 
based on the relative correlation of Cp and Ct. From the report on inhibitory action of CN 
and blood concentration32) and the results of PK/PD analysis, It is also thought that CYA 
status is shown in Figure 13-A. On this basis, it is supposed that the clinical effect of CYA is 
slightly lower than that of TAC50-52). It is plausible that the Ct of CYA can be reduced on a 
temporary basis to avoid nephrotoxicity, as is done with AGs (Figure 13-A). Conversely, 
there is a possibility that Cp is associated with side effects as shown in Figure 13-B. CYA can 
reduce the Cp (Figure 13-D) and can also keep the AUC in the blood concentration time 
curve to elevate the Ct. In fact, CYA shows good results by continuous intravenous infusion 
for hematopoietic stem cell transplantation38). However, it has been found that there is a 
slight difference in the clinical results of the hematopoietic stem cell transplantation40) 
(Figure 14). Therefore, CYA has wide tolerance of blood concentration, even if it is 
administered at various dosages or if it has various blood concentration time curves.  
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Fig. 13. Various relationships of blood concentration curve and the effective and side effect 
ranges, when AUCs are equivalent. 
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CYA and TAC are used equally in clinical practice in terms of the existing therapeutic dose 
and the AUC, and there are no particular problems (Figure 13-C). On the other hand, it is 
thought that a gentle (with AUTL/AUC% high) blood concentration time curve is suitable 
for TAC because its tolerance level is low (Figure 14).  
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Fig. 14. Difference in range of effective and side effect bllod concentrations between CYA 
and TAC. 
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